论文部分内容阅读
目的观察替罗非班在急性心肌梗死介入治疗中的临床疗效及不良反应。方法 120例急性心肌梗死患者,随机分为两组,目的探讨分析替罗非班在急性心梗介入治疗中的临床疗效。回顾性分析2012年1月~2013年6月郑州市第三人民医院收治的120例AMI患者,按照知情同意原则,将所选患者随机分为对照组及治疗组,两组各60例,其中对照组采用阿司匹林、氯吡格雷和肝素的常规冠状动脉介入治疗方法(PCI)治疗,而治疗组则在对照组常规(PCI)治疗的基础上进行替罗非班介入治疗,分析两组患者的临床情况。结果对照组和治疗组比较,治疗组达到Ⅲ级TIMI的患者例数明显多于对照组(P<0.05),患者心脏发生不良事件的概率治疗组明显少于对照组(P<0.05)。结论替罗非班明显减缓急性心肌梗死患者的临床病症,临床上具有重要的推广价值。
Objective To observe the clinical efficacy and side effects of tirofiban in the interventional treatment of acute myocardial infarction. Methods One hundred and twenty patients with acute myocardial infarction were randomly divided into two groups. The aim of the study was to analyze the clinical efficacy of tirofiban in the treatment of acute myocardial infarction. A retrospective analysis of 120 AMI patients admitted to the Third People’s Hospital of Zhengzhou City from January 2012 to June 2013 was conducted. According to the principle of informed consent, the selected patients were randomly divided into control group and treatment group, 60 cases in each group The control group was treated with conventional PCI with aspirin, clopidogrel and heparin, while the treatment group was treated with tirofiban on the basis of PCI in the control group, and the patients in both groups were analyzed Clinical situation. Results Compared with the control group, the number of patients with stage Ⅲ TIMI in the treatment group was significantly more than that of the control group (P <0.05). The probability of adverse cardiac events in the treatment group was significantly less than that in the control group (P <0.05). Conclusion Tirofiban significantly reduces the clinical symptoms of patients with acute myocardial infarction, clinically important promotional value.